Clinical factor for clinicians to choose treatments to refractory ulcerative colitis patients, and the validity of the treatment. - Clinical factor to choose treatments to refractory ulcerative colitis patients, and the validity of it.

agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology0 个研究点目标入组 150 人开始时间: 2016年12月15日最近更新: 2023年10月17日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The clinical response rates at 8 weeks were 74.0% in total, and 73.2% and 74.7% in the anti-TNF and TAC groups. Among the total cases, male sex was responded to the treatment. In the TAC group, high CRP increased the odds of treatment response. The male sex increased the odds of effectiveness only in the TNF group. TAC rather than anti-TNF therapy was an independent risk factor for relapse. A higher Mayo score at 8 weeks also significantly increased the risk for relapse in all cases.

研究设计

研究类型: Observational

入排标准

年龄范围: 16years-old 至 100years-old（—）
性别: All

入选标准

未提供

排除标准

•1.Patients who became observation impossible within 52 weeks after treatment starting 2. Patients whose treatment deviate from health insurance 3. The patient who are judged unsuitable by the researcher.

研究者

发起方

agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology

相似试验

已完成

4 期

GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trialVentilator-Associated Pneumonia (VAP)

JPRN-UMIN000031933Division of Trauma and Surgical Critical Care, Osaka General Medical Center206

已完成

2 期

Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC)ER positive, HER2 negative, Stage II or IIIA [T2-3,N0-2,M0], Primary Postmenopausal Invasive Breast Cancer Patients

JPRN-UMIN000004752Japan Breast Cancer Research Group (JBCRG)58

已完成

不适用

To establish of optimal antiemetic therapy for trastuzumab deruxtecan therapy-induced nausea and vomiting in patients with breast cancer:an open-label, randomized pilot studybreast cancer

JPRN-UMIN000041004Gifu University40

已完成

2 期

KRP-AM1977X Phase II Clinical StudyMild to moderate community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)

JPRN-jRCT2080222226Kyorin Pharmaceutical Co.,LTD129

已完成

2 期

Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy.(JBCRG-11CPA)ER positive, HER2 negative, Stage II or IIIA [T2-3,N0-2,M0], Primary Postmenopausal Invasive Breast Cancer Patients

JPRN-UMIN000004751Japan Breast Cancer Research Group (JBCRG)59